Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / SPONSORED ADS
-
Total 13F shares
-
32,219,336
-
Share change
-
-4,785,817
-
Total reported value
-
$75,069,520
-
Price per share
-
$2.33
-
Number of holders
-
32
-
Value change
-
-$27,169,211
-
Number of buys
-
18
-
Number of sells
-
16
Institutional Holders of GRACELL BIOTECHNOLOGIES INC - SPONSORED ADS (GRCL) as of Q1 2022
As of 31 Mar 2022,
GRACELL BIOTECHNOLOGIES INC - SPONSORED ADS (GRCL) was held by
32 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
32,219,336 shares.
The largest 10 holders included
Temasek Holdings (Private) Ltd, ORBIMED ADVISORS LLC, Frazier Life Sciences Management, L.P., Capital Group International, Inc./CA/, EcoR1 Capital, LLC, FEDERATED HERMES, INC., WELLINGTON MANAGEMENT GROUP LLP, Vivo Capital, LLC, BlackRock Inc., and Paradigm Biocapital Advisors LP.
This page lists
32
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.